Voyager Therapeutics (VYGR) News Today $2.82 -0.10 (-3.42%) Closing price 04:00 PM EasternExtended Trading$2.88 +0.06 (+1.95%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Vestal Point Capital LP Raises Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Vestal Point Capital LP lifted its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 151.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,230,000 shares oMay 21, 2025 | marketbeat.comNASA Engineers Revive Long-Dormant Thrusters on Voyager 1, the Farthest Spacecraft From Earth, in a ‘Miracle Save’May 21, 2025 | msn.comWith 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investorsMay 20, 2025 | uk.finance.yahoo.comBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.39May 19, 2025 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issuedMay 18, 2025 | marketbeat.comVoyager reports breakthrough in brain drug deliveryMay 17, 2025 | uk.investing.comVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy PublicationMay 15, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLCBridgeway Capital Management LLC trimmed its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 72.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,106 shares of the company'sMay 15, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LPDimensional Fund Advisors LP grew its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,380,615 shares of the company's stock after purchasiMay 13, 2025 | marketbeat.comQ2 EPS Forecast for Voyager Therapeutics Reduced by AnalystVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now expects that the compaMay 13, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR Q2 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Stock analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo now expects that the company will post earnings of (May 11, 2025 | marketbeat.comWedbush Equities Analysts Boost Earnings Estimates for VYGRVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Wedbush lifted their Q2 2025 EPS estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings of ($0.31) per share for the quarter, upMay 11, 2025 | marketbeat.comFarallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Farallon Capital Management LLC grew its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,570,700 shares of the company's stock after acquiring an additionalMay 11, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Voyager Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo forecasts that the company will post earnings pMay 10, 2025 | marketbeat.comVoyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating ResultsMay 9, 2025 | finanznachrichten.deRaymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Raymond James Financial Inc. purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,505 shares of the coMay 9, 2025 | marketbeat.comVoyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on MondayVoyager Therapeutics (NASDAQ:VYGR) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-voyager-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comVoyager Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 49.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,900 shares of the company's stock aMay 4, 2025 | marketbeat.comVoyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual MeetingApril 28, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have received an average rating of "Buy" from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy ratingApril 22, 2025 | marketbeat.comVoyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...April 21, 2025 | finance.yahoo.comFY2026 Earnings Forecast for VYGR Issued By Leerink PartnrsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a report released on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo now expects that the companyApril 20, 2025 | marketbeat.com7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 10, 2025 | nasdaq.comVoyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday.April 10, 2025 | marketbeat.comVoyager updates on Alzheimer’s programs ‘compelling,’ says H.C. WainwrightApril 9, 2025 | markets.businessinsider.comADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)ADAR1 Capital Management LLC increased its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 212.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,792 shares of the company's stockApril 9, 2025 | marketbeat.comTD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)April 8, 2025 | markets.businessinsider.com2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 8, 2025 | benzinga.comRaymond James Financial Inc. Takes Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Raymond James Financial Inc. acquired a new position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 131,505 shares of the company's stock, vApril 7, 2025 | marketbeat.comAlfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) StockApril 6, 2025 | insidertrades.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells 10,885 Shares of StockVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.April 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 82,100 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)Prudential Financial Inc. trimmed its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 330,300 shares of the company's stock after selling 82,100April 6, 2025 | marketbeat.comVoyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025April 2, 2025 | nasdaq.comVoyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025March 31, 2025 | finanznachrichten.deVoyager Therapeutics announces new data from two preclinical programsMarch 31, 2025 | markets.businessinsider.comVoyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025March 31, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation oMarch 27, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below 50 Day Moving Average - Here's What HappenedVoyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50 Day Moving Average - Should You Sell?March 25, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 17, 2025 | prnewswire.comHC Wainwright Brokers Boost Earnings Estimates for VYGRVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst P. Trucchio now anticipates that theMarch 17, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for VYGRVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush decreased their Q1 2025 EPS estimates for Voyager Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.37) per share forMarch 17, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for VYGR EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that tMarch 15, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock PriceCanaccord Genuity Group reduced their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday.March 14, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comVoyager Therapeutics price target lowered to $12 from $14 at CanaccordMarch 13, 2025 | markets.businessinsider.comVoyager Therapeutics' (VYGR) Outperform Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday.March 13, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 AnalystsMarch 12, 2025 | benzinga.comVoyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Expectations By $0.24 EPSVoyager Therapeutics (NASDAQ:VYGR - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.March 12, 2025 | marketbeat.com Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Media Mentions By Week VYGR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYGR News Sentiment▼0.550.78▲Average Medical News Sentiment VYGR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYGR Articles This Week▼34▲VYGR Articles Average Week Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Replimune Group News Anavex Life Sciences News Day One Biopharmaceuticals News Trevi Therapeutics News Evolus News Vir Biotechnology News Immatics News Arbutus Biopharma News ChromaDex News AnaptysBio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYGR) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
